1[1]Ely SW,Mentzer RM,Laslay RD,et al.Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine [ J ].J Thorac Cardiovasc Surg,1985,90:549-556
2[2]Hori M,Kitakaze.Adenosine,heart and coronary circulation[ J ].Hypertension,1991,18:565-574
3[3]Fredholm BB,Abbraechio MP,Burnstock G,et al.Nomenclature and classification of purinoceptors[ J ].Pharmacol Revs,1994,46:143-156
4[4]Yellon DM,Baxter GF,Garcia-Dorado D,et al.Ischaemic preconditioning:present position and future directions[Review] [J ].Cardiovasc Res,1998,37:21-33
5[5]Downey J M,Cohen MV.Signal transduction in ischemic preconditioning[Review] [J ].Adv Exp Med Biol,1997,430:39-55
6[6]Baxter GF,pharms MR,Marber,et al.Adenosine receptorinvolvement in a delayed phase of myocardial protection 24 hours after ischemicpreconditioning[J].Circulation,1994,90:2993-3000
7[7]Tskano H,Bolli-R,Tang X-L,et al.Activation of A1 or A3 receptors produces delayed protection against infarction in conscious rabbits by a mechanisminvolving KATP channels[ J ].Circulation,1999,100(Suppl):A56
8[8]Dana A,Yamashita N,Baxter GF,et al.Involvement of protein kinases and manganese-superoxide dismuttase in adenosine induced delayed preconditioning (Abstracts) [J ].J Mol Cell Cardiol,1998,30:A75
9[9]Vander Heide R Reimer K.Effect of adenosine therapy at reperfusion on myocardial infarct size in dogs [ J ].Cardiovasc Res,1996,31:711-718
10[10]Norton ED,Jackson EK.The effects of intravenous infusions of selective adenosine A1-receptor and A2-receptor agonists on myocardial reperfusion injury[ J ].AM Heart J,1992,123:332-338
